PMV Pharmaceuticals reports 46% ORR and plans Q1 2027 NDA filing
PMV Pharmaceuticals says its ovarian cohort generated a 46% ORR and it plans an NDA filing in Q1 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.